Finerenone; HFmrEF/HFpEF; FINEARTS-HF; FINE-HEART

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
Cardiology
FAIR-HF2 Trial: Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure
- Stefan D. Anker, MD, PhD
- Mahir Karakas, MD, PhD, MBA
NYHA FC and Finerenone Response: Clinical Trial Insights
NYHA FC and Finerenone Response: Clinical Trial Insights
Cardiology
NYHA FC and Finerenone Response: Clinical Trial Insights
- John Ostrominski
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
- Jonathan Cunningham, MD
Advances in Care for ATTR-CM: Current and Emerging Strategies
Advances in Care for ATTR-CM: Current and Emerging Strategies
Heart Matters
Advances in Care for ATTR-CM: Current and Emerging Strategies
- Gautam Nayak, MD

FINE-HEART Pooled Analysis